Tri Chemical Laboratories Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Tri Chemical Laboratories heeft een totaal eigen vermogen van ¥28.8B en een totale schuld van ¥1.7B, wat de schuld-eigenvermogensverhouding op 6% brengt. De totale activa en totale passiva bedragen respectievelijk ¥33.5B en ¥4.8B. De EBIT Tri Chemical Laboratories is ¥2.8B waardoor de rentedekking 132.7 is. Het heeft contanten en kortetermijnbeleggingen van ¥9.5B.

Belangrijke informatie

6.0%

Verhouding schuld/eigen vermogen

JP¥1.73b

Schuld

Rente dekkingsratio	132.7x
Contant	JP¥9.53b
Aandelen	JP¥28.77b
Totaal verplichtingen	JP¥4.76b
Totaal activa	JP¥33.53b

Recente financiële gezondheidsupdates

Is Tri Chemical Laboratories (TSE:4369) A Risky Investment?

May 01

Recent updates

Tri Chemical Laboratories' (TSE:4369) Weak Earnings May Only Reveal A Part Of The Whole Picture

Sep 06

Tri Chemical Laboratories Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Sep 03

Tri Chemical Laboratories Inc.'s (TSE:4369) 37% Cheaper Price Remains In Tune With Earnings

Aug 05

Is Tri Chemical Laboratories (TSE:4369) A Risky Investment?

May 01

The Returns On Capital At Tri Chemical Laboratories (TSE:4369) Don't Inspire Confidence

Apr 01

Investors Appear Satisfied With Tri Chemical Laboratories Inc.'s (TSE:4369) Prospects As Shares Rocket 30%

Feb 29

Estimating The Intrinsic Value Of Tri Chemical Laboratories Inc. (TSE:4369)

Feb 28

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ¥19.7B ) 4369 } overtreffen de korte termijn passiva ( ¥3.2B ).

Langlopende schulden: De kortetermijnactiva 4369 ( ¥19.7B ) overtreffen de langetermijnschulden ( ¥1.5B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 4369 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 4369 is de afgelopen 5 jaar gedaald van 37.3% naar 6%.

Schuldendekking: De schuld van 4369 wordt goed gedekt door de operationele kasstroom ( 59% ).

Rentedekking: De rentebetalingen op de schuld van 4369 worden goed gedekt door EBIT ( 132.7 x dekking).

Tri Chemical Laboratories Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is Tri Chemical Laboratories (TSE:4369) A Risky Investment?

Recent updates

Tri Chemical Laboratories Inc. to Report Q3, 2025 Results on Nov 29, 2024

Investor sentiment deteriorates as stock falls 19%

Tri Chemical Laboratories' (TSE:4369) Weak Earnings May Only Reveal A Part Of The Whole Picture

Tri Chemical Laboratories Inc. Provides Consolidated Earnings Guidance for the Full Fiscal Year Ending January 31, 2025

Tri Chemical Laboratories Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Tri Chemical Laboratories Inc.'s (TSE:4369) 37% Cheaper Price Remains In Tune With Earnings

Investor sentiment deteriorates as stock falls 24%

New major risk - Share price stability

Price target decreased by 10% to JP¥6,025

Tri Chemical Laboratories Inc. to Report Q2, 2025 Results on Aug 30, 2024

Price target increased by 12% to JP¥6,700

Tri Chemical Laboratories Inc. Provides Dividend Guidance for the Fiscal Year Ending January 31, 2025

First quarter 2025 earnings released: EPS: JP¥24.99 (vs JP¥30.53 in 1Q 2024)

Is Tri Chemical Laboratories (TSE:4369) A Risky Investment?

Tri Chemical Laboratories Inc. to Report Q1, 2025 Results on May 31, 2024

The Returns On Capital At Tri Chemical Laboratories (TSE:4369) Don't Inspire Confidence

Now 22% undervalued

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Tri Chemical Laboratories Inc., Annual General Meeting, Apr 25, 2024

Now 20% overvalued after recent price rise

Price target increased by 9.5% to JP¥5,200

Investors Appear Satisfied With Tri Chemical Laboratories Inc.'s (TSE:4369) Prospects As Shares Rocket 30%

Estimating The Intrinsic Value Of Tri Chemical Laboratories Inc. (TSE:4369)

Tri Chemical Laboratories Inc. to Report Fiscal Year 2024 Results on Mar 15, 2024

Upcoming dividend of JP¥30.00 per share at 0.8% yield

Now 21% overvalued after recent price rise

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 18% to JP¥4,500

Now 21% undervalued

New minor risk - Share price stability

Now 22% undervalued

Tri Chemical Laboratories Inc. to Report Q3, 2024 Results on Nov 30, 2023

Price target increased by 7.0% to JP¥3,800

Consensus revenue estimates fall by 16%

Tri Chemical Laboratories Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending January 31, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Tri Chemical Laboratories Inc. to Report Q2, 2024 Results on Aug 31, 2023

Consensus EPS estimates fall by 13%

Tri Chemical Laboratories Inc. Provides Consolidated Earnings Guidance for the First Half and Fiscal Year Ending January 31, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 22% undervalued after recent price drop

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 19%

Price target decreased by 13% to JP¥3,333

Upcoming dividend of JP¥22.00 per share

Tri Chemical Laboratories Inc. to Report Fiscal Year 2023 Results on Mar 15, 2023

Tri Chemical Laboratories Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending January 31, 2023

Now 21% undervalued

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased to JP¥3,750

No independent directors

Price target decreased to JP¥3,750

Investor sentiment improved over the past week

Tri Chemical Laboratories Inc. to Report Q3, 2023 Results on Nov 30, 2022

Tri Chemical Laboratories Inc. Provides Dividend Guidance for the Fiscal Year Ending January 31, 2023

Tri Chemical Laboratories Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending January 31, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations

Tri Chemical Laboratories Inc. Provides Dividend Guidance for the Fiscal Year Ending January 31, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

No independent directors

Tri Chemical Laboratories Inc. to Report Q1, 2023 Results on May 31, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Upcoming dividend of JP¥17.00 per share

Tri Chemical Laboratories Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending January 31, 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to JP¥4,200

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS JP¥28.83 (vs JP¥29.83 in 2Q 2021)

First quarter 2022 earnings released: EPS JP¥29.35 (vs JP¥27.65 in 1Q 2021)